All In Biotech

Drug Trial Radar · NCT00099502

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.

Last checked: Nov 20, 2026Latest source record: Dec 19, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,244 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,244

Actual

Start

Nov 2003

Primary completion

Not stated

Study completion Aug 2007

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Dec 16, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine * whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms * whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)Drug

    250mcg administered s.c. every other day

  • Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)Drug

    500mcg administered s.c. every other day

  • CopaxoneDrug

    20 mg administered s.c. once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hazard ratio for relapsesTime frame: During the first and during the second 52 weeks

Locations

199 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Cullman, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Berkeley, California

  • Site not named

    La Jolla, California

  • Site not named

    Sacramento, California

  • Site not named

    San Francisco, California

  • Site not named

    Englewood, Colorado

  • Site not named

    Fort Collins, Colorado

  • Site not named

    Wilmington, Delaware

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Miami, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Des Moines, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Detroit, Michigan

  • Site not named

    Duluth, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Henderson, Nevada

  • Site not named

    Reno, Nevada

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Albany, New York

  • Site not named

    Mineola, New York

  • Site not named

    Rochester, New York

  • Site not named

    Stony Brook, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    High Point, North Carolina

Showing 40 of 199 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.